<DOC>
	<DOCNO>NCT00972465</DOCNO>
	<brief_summary>Nimotuzumab IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The study assess safety , efficacy combination Nimotuzumab administer concomitantly chemotherapy patient advanced colorectal cancer .</brief_summary>
	<brief_title>Study Nimotuzumab Treat Colorectal Cancer</brief_title>
	<detailed_description>Nimotuzumab Irinotecan administer patient disease progression development toxicity preclude treatment.Irinotecan administer every 14 day , dosage 180mg/m2 ; Nimotuzumab treatment divide 3 levels:200mg/w,400mg/w,600mg/w , weekly.The patients'blood test liver renal function test monitor weekly , physical exam reassessment tumor perform every 6 week , total result CR PR , result 6th 12th week compare .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Informed consent form sign perform study 's specific procedure . ECOG performance status 02 . Age &gt; 18，both gender . Metastatic colorectal cancer confirm pathology , locally advance unresectable colorectal cancer , postoperative recurrence metastasis colorectal cancer Disease progression receive oxaliplatin ± fluorouracil firstline treatment At least 1 measurable lesion , ( long diameter≥ 1 cm spiral compute tomography ( CT ) scan MRI ) Life expectancy 3 month . Kras wild type Use effective contraceptive method patient sex risk conception and/or pregnancy . Liver metastasis , lesion small 50 % liver ; Lung metastasis , lesion small 30 % lung Haemoglobin≥90g/L , granulocyte≥1.5×109/L , WBC ≥3×109/L , platelet count≥100×109/L TBIL≤ 1.5 x ULN , ALK≤ 2.5 x ULN ≤ 5ULN（Liver metastasis），AST ALT≤ 2.5 x ULN ≤ 5ULN（Liver metastasis） , Creatinine ≤ 1.5 x ULN No brain metastasis Previous radiotherapy lesion within three month Other first line chemoagents treatment except oxaliplatin ± fluorouracil Received anti EGFR monoclonal antibody treatment Complete incomplete intestinal obstruction Participation interventional clinical trial within 1 month Psychiatric disease affect cognitive ability , include brain metastasis Peripheral neuropathy lesion I stage History serious allergic allergy Pregnant breastfeed woman Patients history Serious lung hear disease Other malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>nimotuzumab colorectal cancer chemotherapy</keyword>
</DOC>